-- Cochlear's (ASX:COH) current volume delays are not structural as its volume opportunity for implants remains strong, Jefferies said in a Wednesday note.
Jefferies said that US Medicare Advantage and commercial insurance providers require prior authorization for cochlear implantation procedures, which is causing delays in cochlear implant procedure volumes.
Cochlear needs to continue promoting the benefits of cochlear implants while also expanding its advocacy programs to support patient access and awareness, the investment firm added.
Jefferies kept a buy rating on Cochlear with a price target of AU$137.